fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-04-30 Clavis Pharma (Norway)
Ventana Medical Systems (USA)
hENT1 antibody to be used in companion diagnostic for Clavis Pharma's drug candidate CP-4126 and the hybridoma cell line that produces the antibody.
/ pancreatic cancer
licensing
See details
2010-04-30 CEVEC Pharmaceuticals (Germany)
Aragen Bioscience (USA)
recombinant human cell lines expressing biotherapeutic proteins and antibodies licensing
See details
2010-04-29 ARTES Biotechnology (Germany)
Q Chip (UK)
sustained release formulations of interferon alpha 2a
these formulations will use Q Chip’s bioencapsulation technologies. / chronic hepatitis B and C
development
other
See details
2010-04-29 Bicycle Therapeutics (UK)
EPFL (Switzerland)
bicyclic peptides licensing
other
See details
2010-04-29 Galapagos (Belgium)
CHDI Foundation (USA)
/ Huntington's disease R&D
See details
2010-04-28 ProBioGen (Germany)
Virdante Biopharmaceuticals (USA)
cell line development and process engineering services for therapeutic proteins. / autoimmune and inflammatory diseases manufacturing
other
See details
2010-04-28 Pepscan (The Netherlands)
Immunovo
therapeutic vaccine portfolio that includes an anti-VEGF-A vaccine that could be useful for the treatment of certain cancers.
licensing
development
other
See details
2010-04-27 Ipsen (France)
Invida (Singapore)
Diphereline®/Decapeptyl®, Somatuline® Autogel® and Increlex® commercialization/ distribution
marketing/ promotion
See details
2010-04-27 PolyTherics (UK)
undisclosed pharmaceutical company
proprietary drug modification technologies to a target protein R&D
other
See details
2010-04-27 Cellectis (France)
VIB (Belgium)
/ haemophilia R&D
See details
2010-04-23 Clavis Pharma (Norway)
Clovis Oncology (USA)
Ventana Medical Systems (USA)
hENT1 companion diagnostic to CP-4126 (lipid-conjugated form of the anti-cancer drug gemcitabine) / pancreatic cancer development
See details
2010-04-16 4SC (Germany)
Nexigen (Germany)
/ cancer R&D
development
See details
2010-04-15 Swedish Orphan Biovitrum (Sweden)
Pharming Group (The Netherlands)
Rhucin® (conestat alfa - recombinant human C1 inhibitor)
/ Hereditary angioedema
commercialization/ distribution
See details
2010-04-13 Mersana Therapeutics (USA)
Teva Pharmaceuticals (Israel)
XMT-1107 is a conjugate of a novel analog of fumagillin (angiogenesis inhibitor) and Fleximer® (biodegradable and bio-inert polymer that can be chemically linked to small molecules, biologics and nucleic acids to enhance their pharmacokinetic and safety profiles).
/ cancer and other potential indications
R&D
licensing
See details
2010-04-12 Proximagen Neuroscience (UK)
Upsher-Smith (USA)
tonabersat / epilepsy licensing
commercialization/ distribution
development
marketing/ promotion
See details
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [65]